宏利消费红利指数A（008928）基金经理为李婷婷。 截至发稿，李婷婷累计任职时间4年59天，现任基金资产总规模23.22亿元，任职期间最佳基金回报 43.8%， 任职期间最差基金回报-35.89%。 从众兴菌业十大流通股东角度 数据显示，宏利基金旗下1只基金位居众兴菌业十大流通股东。宏利消费红利指数A（008928）三季度 增持36.31万股，持有股数349.8万股，占流通股的比例为0.9%。根据测算，今日浮盈赚取约297.33万 元。 宏利消费红利指数A（008928）成立日期2020年3月26日，最新规模7.2亿。今年以来亏损0.21%，同类 排名4898/5580；近一年收益8.18%，同类排名3738/4297；成立以来收益58.61%。 从基金十大重仓股角度 2月24日，众兴菌业涨5.2%，截至发稿，报17.21元/股，成交1.10亿元，换手率1.67%，总市值67.68亿 元。 资料显示，天水众兴菌业科技股份有限公司位于甘肃省天水市秦州区建设路185号，成立日期2005年11 月18日，上市日期2015年6月26日，公司主营业务涉及食用菌研发、工厂化培植与销售。主营业务收入 构成为：双孢菇63. ...

Group 1 - The core viewpoint of the news is that Zhongxing Junye's stock has seen a continuous increase, with a total rise of 8.87% over three days, reflecting positive market sentiment towards the company [1] - As of the report date, Zhongxing Junye's stock price is 16.98 yuan per share, with a market capitalization of 6.677 billion yuan and a trading volume of 357 million yuan [1] - The company's main business involves the research, industrial cultivation, and sales of edible mushrooms, with the revenue composition being 63.04% from Agaricus bisporus, 35.32% from enoki mushrooms, and smaller contributions from other products [1] Group 2 - According to data, one of the funds under GF Fund has a significant holding in Zhongxing Junye, specifically the GF Quality Life Mixed A Fund, which holds 1.8337 million shares, accounting for 4.85% of the fund's net value [2] - The GF Quality Life Mixed A Fund has generated a floating profit of approximately 3.67 million yuan today, with a total floating profit of 2.536 million yuan during the three-day increase [2] - The fund manager, Wang Peng, has been in position for over 6 years, with the fund's total asset size at 1.092 billion yuan and a best return of 74.86% during his tenure [2]

Group 1: Core Insights - The capital expenditure and capacity reduction in the edible mushroom industry are gradually being realized, leading to reduced supply pressure and potential price stabilization for edible mushrooms [1] - Leading companies in the industry have significant advantages in scale, breeding technology, and management, which are expected to improve profitability [1] - The artificial cultivation of Cordyceps sinensis is entering a rapid development phase due to increasing health awareness and advancements in cultivation technology, with companies that have forward-looking capacity and technological layouts likely to show greater growth potential [1] Group 2: Cordyceps Sinensis Market - The natural scarcity of Cordyceps sinensis is increasing, with ongoing advancements in large-scale artificial cultivation [2] - The demand for Cordyceps sinensis is rising due to its various health benefits, with applications expanding in pharmaceuticals, health products, and cosmetics [2] - The supply of wild Cordyceps sinensis is declining, and the continuous advancement of artificial cultivation is improving the industry chain [2] Group 3: Edible Mushroom Industry - The edible mushroom industry is experiencing continuous growth, with a projected CAGR of 6.0% for the national edible mushroom output value from 2019 to 2024 [3] - The market for enoki mushrooms is stabilizing at the bottom price level, with leading companies reducing capacity to alleviate market supply pressure [3] - The profitability of button mushrooms remains stable, with a daily industrial output of 867 tons in 2023, supported by high market share among leading companies [3] - The price of king oyster mushrooms is also stabilizing, with demand supported by household consumption and high-end dining, while leading companies are reducing capital expenditure [3]

Summary of the Conference Call Transcript Industry Overview - **Industry Focus**: Edible Mushroom Industry and Cordyceps Sinensis (冬虫夏草) - **Market Growth**: The edible mushroom industry is experiencing a continuous growth trend, with a projected compound annual growth rate (CAGR) of 6.0% from 2019 to 2024 according to the China Edible Mushroom Association [1] Key Insights on Cordyceps Sinensis - **Demand and Supply Dynamics**: There is a sustained increase in demand for Cordyceps Sinensis, with product forms becoming more diverse. Conversely, the supply of wild Cordyceps is declining, while large-scale artificial cultivation is advancing. This may lead to long-term price increases or strong fluctuations [1] - **Policy Support**: Government policies are encouraging the research and cultivation of endangered medicinal materials and the development of substitutes. Continuous technological advancements in artificial cultivation are being made [1] - **Company Initiatives**: Several companies are strategically positioning themselves in the market. For instance, Dongyangguang has an annual production capacity exceeding 60 tons, while Zhongxing Junye is developing factory-based cultivation projects, showing positive profit trends. Xue Rong Biological is accumulating technology for artificial cultivation of Cordyceps Sinensis [1] Insights on the Edible Mushroom Industry - **Market Structure**: The industry is optimizing its market structure, with production capacity returning to rational levels. Leading companies like Zhongxing Junye maintain over 40% market share and a gross margin exceeding 30% [5] - **Price Stabilization**: Prices for various mushroom types, including Enoki mushrooms and Pleurotus eryngii, are stabilizing at the bottom due to supply adjustments by leading companies like Xue Rong Biological and Zhongxing Junye, which are reducing production capacity to alleviate supply pressure [2][3][7] - **Profitability**: The profitability of the double mushroom segment remains stable, supported by sufficient supply and demand driven by the restaurant sector [6][3] Investment Recommendations - **Edible Mushroom Sector**: As companies reduce capital expenditures and production capacity, supply pressure is expected to ease, leading to potential price stabilization and upward movement. Leading enterprises are positioned to improve profitability due to their advantages in scale, technology, and management [8] - **Cordyceps Sinensis Sector**: With rising health awareness, improving policies, and mature artificial cultivation technologies, the artificial cultivation of Cordyceps Sinensis is entering a phase of large-scale industrial development. Companies with forward-looking capacity and technological layouts are expected to show greater growth potential [8] - **Key Companies**: Zhongxing Junye and Xue Rong Biological are highlighted as significant players in the industry [8] Risk Factors - **Market Competition**: Increased competition in the market poses a risk [9] - **Food Safety**: Potential food safety risks could impact the industry [9] - **Innovation Risks**: Risks associated with research and development not meeting expectations [9] - **Raw Material Costs**: Rising costs of raw materials present a financial risk [9]

Investment Rating - The report assigns an investment rating of "Positive" for the industry, marking it as the first rating issued [2]. Core Insights - The edible fungus industry is experiencing growth, with a projected compound annual growth rate (CAGR) of 6.0% for the national edible fungus output value from 2019 to 2024. The market structure is optimizing as production capacity returns to rational levels [5][6]. - The demand for Cordyceps sinensis is increasing due to its various health benefits, and the supply is becoming scarcer due to overharvesting and climate change. This is expected to lead to long-term price increases or strong fluctuations [5][6]. - The report highlights the ongoing technological advancements and policy improvements that are creating new opportunities for the artificial cultivation of Cordyceps sinensis, which is transitioning into a rapid industrialization phase [5][6]. Summary by Sections 1. Cordyceps Sinensis: Continuous Advancement in Large-Scale Artificial Cultivation - The industry chain for Cordyceps sinensis is continuously improving, with applications expanding across pharmaceuticals, health products, and cosmetics [5][9]. - The price of wild Cordyceps sinensis is expected to remain strong due to its increasing scarcity, with prices returning to 210,000-220,000 yuan per kilogram in 2023 [5][28]. - Policies are being implemented to ensure sustainable harvesting and scientific protection of Cordyceps sinensis, promoting the development of artificial cultivation [5][30]. 2. Edible Fungi: Market Structure Optimization and Rational Return of Production Capacity - The edible fungus industry is witnessing stable growth, with the production of enoki mushrooms stabilizing at over 5,300 tons per day in 2023, and the price is expected to recover from its bottom [5][6]. - The production of button mushrooms is stable, with a daily output of 867 tons in 2023, and leading companies maintain a high market share [5][6]. - The demand for king oyster mushrooms is also improving, supported by household consumption and high-end dining, with industrial production reaching 349 tons per day in 2023 [5][6]. 3. Investment Recommendations - The report suggests that the edible fungus industry will see price stabilization and upward movement due to reduced supply pressure from capital expenditure and capacity cuts by enterprises [5][6]. - In the Cordyceps sinensis sector, companies with advanced capacity and technological layouts are expected to show greater growth potential as health awareness increases [5][6].

Group 1 - The core point of the news is that Zhongxing Junye's stock price dropped by 5% to 15.76 CNY per share, with a trading volume of 162 million CNY and a turnover rate of 2.57%, resulting in a total market capitalization of 6.197 billion CNY [1] - Zhongxing Junye, established on November 18, 2005, and listed on June 26, 2015, is primarily engaged in the research, industrial cultivation, and sales of edible mushrooms [1] - The company's main revenue sources are: 63.04% from Agaricus bisporus, 35.32% from Enoki mushrooms, 0.89% from Cordyceps, 0.53% from ecological breeding of Cordyceps sinensis, and 0.22% from other products [1] Group 2 - Manulife Fund's Manulife Consumer Dividend Index A (008928) is among the top ten circulating shareholders of Zhongxing Junye, having increased its holdings by 363,100 shares to a total of 3.498 million shares, representing 0.9% of the circulating shares [2] - The fund has incurred an estimated floating loss of approximately 2.9033 million CNY today [2] - The fund was established on March 26, 2020, with a current size of 720 million CNY, and has a year-to-date return of 0.21%, ranking 5031 out of 5551 in its category [2] Group 3 - The fund manager of Manulife Consumer Dividend Index A is Li Tingting, who has been in the position for 4 years and 33 days, managing total assets of 2.322 billion CNY [3] - During her tenure, the best fund return was 46.22%, while the worst return was -35.89% [3] Group 4 - In the fourth quarter, Manulife Consumer Dividend Index A reduced its holdings in Zhongxing Junye by 1.269 million shares, bringing the total to 2.229 million shares, which constitutes 2.84% of the fund's net value, making it the fifth-largest holding [4] - The estimated floating loss for the fund today is approximately 1.8501 million CNY [4]

Core Viewpoint - The company focuses on the research, industrial cultivation, and sales of edible and medicinal mushrooms, such as enoki and Agaricus bisporus, while also engaging in a land use rights project through a bidding process in Tianshui City [1]. Group 1: Business Operations - The main business of the company includes the development, factory cultivation, and sales of edible and medicinal mushrooms [1]. - The company emphasizes enhancing its profitability to provide better returns for investors [1]. Group 2: Strategic Development - The company’s subsidiary, Tianshui Yusheng Real Estate Co., Ltd., acquired land use rights through participation in a bidding project related to urban renewal financing in Tianshui City [1]. - The company plans to advance this project opportunistically, considering market cycles and its development strategy, without impacting its core business [1].

Summary of Zhongxing Junye (002772.SZ) 2025 Annual Performance Forecast Company Overview - **Company**: Zhongxing Junye (002772.SZ) - **Industry**: Agriculture, specifically mushroom cultivation Key Financial Metrics - **Net Profit Attributable to Shareholders**: - Forecasted range: 300 million to 350 million CNY - Year-on-year growth: 134.32% to 173.37% [1] - **Net Profit Excluding Non-Recurring Gains and Losses**: - Forecasted range: 268.5 million to 318.5 million CNY - Year-on-year growth: 192.57% to 247.06% [2] Core Reasons for Significant Growth - **Sales Performance**: - The sales price of Agaricus bisporus (common mushroom) has remained stable with an upward trend [3] - **Production Capacity**: - The Hubei Zhongxing base is operating at full capacity, contributing to increased sales and profitability [4] Additional Important Insights - The substantial growth in net profit is attributed to both price stability and increased production capacity, indicating a strong market position and operational efficiency [5]

Core Viewpoint - Tianshui Zhongxing Mushroom Industry Co., Ltd. (referred to as "Zhongxing Mushroom") expects significant profit growth for the fiscal year 2025, driven by rising product prices and increased production capacity [1][2] Financial Performance - The company anticipates a net profit attributable to shareholders of 300 million to 350 million yuan, representing a year-on-year increase of 134.32% to 173.37% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 269 million and 319 million yuan, reflecting a year-on-year growth of 192.57% to 247.06% [1] - Financial expenses are expected to decrease by approximately 20 million yuan due to changes in market interest rates, exchange rates, and interest capitalization [1] Business Strategy and Development - Zhongxing Mushroom focuses on the research, cultivation, and sales of edible and medicinal fungi, with leading production capacities for enoki mushrooms and button mushrooms [1] - The company has established production bases in multiple provinces, including Gansu, Shaanxi, Shandong, Jiangsu, Henan, Sichuan, Anhui, and Hubei [1] - In 2025, the company plans to diversify its business by advancing the industrialization of Cordyceps sinensis and other rare edible and medicinal fungi [1][2] Investment Projects - In June 2025, Zhongxing Mushroom signed investment agreements to establish Sichuan Zhongxing Mushroom Technology Co., Ltd. with an investment of 700 million yuan for a "Southwest Headquarters Base Project" focused on the industrialization of Cordyceps sinensis [2] - The wholly-owned subsidiary, Tianshui Zhong'an Biotechnology Co., Ltd., will also shift its production focus to the industrialization of Cordyceps sinensis [2] - Another subsidiary, Meishan Changhong Agricultural Biotechnology Co., Ltd., will implement technological upgrades starting May 2024 to explore the research and cultivation of rare edible and medicinal fungi [2]

Core Viewpoint - Zhongxing Junye (002772) expects a significant increase in net profit for 2025, projecting a growth of 134.32% to 173.37% year-on-year, driven by rising sales prices and increased production capacity [4] Financial Performance - The company forecasts a net profit attributable to shareholders of 300 million to 350 million yuan for 2025, with a non-recurring net profit expected to be between 269 million and 319 million yuan, reflecting a year-on-year growth of 192.57% to 247.06% [4] - Basic earnings per share are projected to be between 0.8 yuan and 0.93 yuan [4] - As of January 26, the company's price-to-earnings ratio (TTM) is approximately 17.67 to 20.62 times, with a price-to-book ratio (LF) of about 1.82 times and a price-to-sales ratio (TTM) of around 3.1 times [4] Business Operations - The main business of the company includes research, industrial cultivation, and sales of edible mushrooms [13] - The increase in profit is attributed to stable sales prices of Agaricus bisporus, increased production and sales from the Hubei Zhongxing base, and a recovery in sales prices of enoki mushrooms in the second half of the year [13] - Financial expenses have decreased by approximately 20 million yuan year-on-year due to changes in market interest rates, exchange rates, and interest capitalization [13] Historical Financial Data - Historical net profit and non-recurring net profit data shows a consistent upward trend, with projections indicating continued growth into 2025 [14] - The year-on-year growth rates for net profit and non-recurring net profit are expected to be significantly positive, indicating strong operational performance [14]